Ultimovacs
About Ultimovacs
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs that require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe and the USA. The company and its proprietary technology are based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is a limited public liability company listed on the Oslo Stock Exchange in Norway.
Company Metrics
- Employees: 11-50
- Monthly Visits: 5799
- Tech Stack: None active products
Financial Information
- Estimated Revenue: $1M to $10M
- Total Funding: 270000000 NOK
- Last Funding: 270000000 NOK (Post-IPO Equity)
- Funding Status: IPO
Technology Stack
Ultimovacs actively uses None products in their tech stack.
Market Presence
Industries: Biotechnology, Health Care, Pharmaceutical
Headquarters: Oslo, Oslo, Norway
Employees
- Jens Bjorheim - Chief Medical Officer (LinkedIn)
- Ton Berkien - Chief Business Officer (LinkedIn)